On May 3 and 5, the American Society of Clinical Oncology (ASCO) and the U.S. Food and Drug Administration (FDA) will host a workshop to discuss research and clinical challenges for dose optimization and highlight strategies to improve dose optimization for anticancer agents. We invite you to join us for this important discussion.
This workshop is a follow-up to a workshop held in February 2021 on oral adherence. At that time, ASCO and FDA identified a primary barrier to adherence is that labeled doses may be higher than necessary to achieve efficacy and have poor tolerability for patients. A strategy identified to improve adherence was to pursue dose optimization strategies that maintain efficacy while minimizing toxicity.